<- Go Home
Mainz Biomed N.V.
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
Market Cap
$5.3M
Volume
168.0K
Cash and Equivalents
$977.8K
EBITDA
-$21.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$541.0K
Profit Margin
58.98%
52 Week High
$1.79
52 Week Low
$0.19
Dividend
N/A
Price / Book Value
-1.28
Price / Earnings
-0.18
Price / Tangible Book Value
-0.72
Enterprise Value
$12.6M
Enterprise Value / EBITDA
-0.59
Operating Income
-$22.0M
Return on Equity
4333.72%
Return on Assets
-99.24
Cash and Short Term Investments
$977.8K
Debt
$8.3M
Equity
-$4.1M
Revenue
$917.2K
Unlevered FCF
-$11.9M
Sector
Biotechnology
Category
N/A